Recent updates in chronic obstructive pulmonary disease

Postgraduate Medicine

Volumn 128, Issue 2, 2016, Pages 231-238

  Garvey, Christine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Comorbidities; Exacerbations; Exercise; Physical activity; Smoking cessation

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL;

ANXIETY; ARTICLE; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; EXERCISE; HUMAN; INFECTION; INFLUENZA; LUNG CANCER; PATIENT CARE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PNEUMOCOCCAL INFECTION; SMOKING CESSATION; VACCINATION; COMPLICATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84964026863     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1118352     Document Type: Article

References (94)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. 2015. [cited 2015 Jul 12]. Available from: http:// www.goldcopd.org/
2. World Health Organization. Chronic respiratory diseases: burden of COPD [Internet]. 2015 [cited 2015 Oct 9]. Available from: http:// www.who.int/respiratory/copd/burden/en/
3. Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Hyattsville, MD: National Center for Health Statistics 2012. Natl Vital Stat Rep. 2012;61(6):1-65.
4. Prevention. CfDCa. Chronic obstructive pulmonary disease among adults-United States. 2011. MMWR. 2012;61(46):938-943.
5. Porszasz J, Emtner M, Goto S, et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest. 2005;128 (4):2025-2034.
6. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105(1):57-66.
7. Van Dijk W, Tan W, Li P, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Ann Fam Med. 2015;13(1):41-48.
8. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586.
9. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880-887.
10. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.
11. Van DerMolen T,Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13.
12. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
13. Celli BR, Cote CG, Marin JM, et al. Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
14. Cunningham TJ, Ford ES, Rolle IV, et al. Associations of selfreported cigarette smoking with chronic obstructive pulmonary disease and co-morbid chronic conditions in the United States. COPD. 2015;12(3):276-286.
15. O'Donnell DE, Gebke KB. Examining the role of activity, exercise, and pharmacology in mild COPD. Postgrad Med. 2014;126(5):135-145.
16. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155 (3):179-191.
17. Garvey C. Identification of patients with early COPD. Curr Respir Med Rev. 2014;9(6):407-417.
18. Egan C, Deering BM, Blake C, et al. Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. Respir Med. 2012;106(12):1671-1679.
19. Marchetti N, Criner GJ. Surgical approaches to treating emphysema: lung volume reduction surgery, bullectomy, and lung transplantation. Semin Respir Crit Care Med. 2015;36(4):592-608.
20. Mineshita M, Slebos DJ. Bronchoscopic interventions for chronic obstructive pulmonary disease. Respirology. 2014;19(8):1126-1137.
21. Deslee G, Klooster K, Hetzel M, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax. 2014;69(11):980-986.
22. Gagnon P, Saey D, Provencher S, et al. Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med. 2012;106(12):1695-1705.
23. Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695-708.
24. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixeddose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969-979.
25. Blair HA, Deeks ED. Umeclidinium/Vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75(1):61-74.
26. Pelaia G, Maselli R, Matera MG. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. Pharmacology. 2014;94 (5-6):249-258.
27. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
28. Clark TW, Medina MJ, Batham S, et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76-86.
29. Wu X, Chen D, Gu X, et al. Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis. Mol Biol Rep. 2014;41(7):4743-4751.
30. Garvey C, Ortiz G. Exacerbations of chronic obstructive pulmonary disease. Open Nurs J. 2012;6:13-19.
31. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363 (12):1128-1138.
32. Magda S. Susceptibility to exacerbation in chronic obstructive pulmonary disease-data from the ECLIPSE study. Maedica (Buchar). 2010;5(3):223-224.
33. Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.
34. Overbeek JA, Penning-van Beest FJ, Balp MM, et al. Burden of exacerbations in patients with moderate to very severe COPD in the Netherlands: a real-life study. COPD. 2015;12(2):132-143.
35. Alahmari AD, Patel AR, Kowlessar BS, et al. Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:98.
36. Rubinsztajn R, Przybylowski T, Maskey-Warzechowska M, et al. Effect of exacerbation frequency on body composition and serum ghrelin and adiponectin concentrations in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2014;124(7-8):403-409.
37. Nici L, ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient. Proc Am Thorac Soc. 2012;9(1):9-18.
38. Woods JA, Wheeler JS, Finch CK, et al. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:421-430.
39. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
40. Jo YS, Choi SM, Lee J, et al. The relationship between chronic obstructive pulmonary disease and comorbidities: a cross-sectional study using data from KNHANES 2010-2012. Respir Med. 2015;109 (1):96-104.
41. Echave-Sustaeta JM, Comeche Casanova L, Cosio BG, et al. Comorbidity in chronic obstructive pulmonary disease. Related to disease severity? Int J Chron Obstruct Pulmon Dis. 2014;9:1307-1314.
42. Sidney S, Sorel M, Quesenberry CP Jr., et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068-2075.
43. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115-122.
44. Black-Shinn JL, Kinney GL, Wise AL, et al. Cardiovascular disease is associated with COPD severity and reduced functional status and quality of life. Copd. 2014;11(5):546-551.
45. Sievi NA, Senn O, Brack T, et al. Impact of comorbidities on physical activity in COPD. Respirology. 2015;20(3):413-418.
46. McNamara RJ, McKeough ZJ, McKenzie DK, et al. Physical comorbidities affect physical activity in chronic obstructive pulmonary disease: a prospective cohort study. Respirology. 2014;19(6):866-872.
47. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc. 2014;15(8):576-581.
48. Fisher K, Stefan M, Darling C, et al. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure (The Worcester Heart Failure Study). Chest. 2015;147 (3):637-645.
49. Carlin BW. COPD and associated comorbidities: a review of current diagnosis and treatment. Postgrad Med. 2012;124(4):225-240.
50. Graat-Verboom L, Spruit MA, Van Den Borne BE, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med. 2009;103(8):1143-1151.
51. Cielen N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. Biomed Res Int. 2014;2014:965764.
52. Coventry PA. Does pulmonary rehabilitation reduce anxiety and depression in chronic obstructive pulmonary disease? Curr Opin Pulm Med. 2009;15(2):143-149.
53. Pumar MI, Gray CR, Walsh JR, et al. Anxiety and depression-important psychological comorbidities of COPD. J Thorac Dis. 2014;6 (11):1615-1631.
54. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345-349.
55. Raviv S, Hawkins KA, DeCamp MM Jr., et al. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. Am J Respir Crit Care Med. 2011;183(9):1138-1146.
56. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research G. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333-339.
57. Lee SJ, Lee J, Park YS, et al. Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer. J Thorac Oncol. 2014;9(6):812-817.
58. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-258.
59. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-407.
60. Martinez-Garcia MA, De La Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-tosevere chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823-831.
61. Caughey GE, Preiss AK, Vitry AI, et al. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36(10):3009-3014.
62. Rogliani P, Calzetta L, Segreti A, et al. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 2014;51(6):933-940.
63. Garcia-Rio F, Soriano JB, Miravitlles M, et al. Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):e105220.
64. Kumar R, Nagar D, Mallick A, et al. Obstructive sleep apnoea and atopy among middle aged chronic obstructive pulmonary disease and bronchial asthma patients. J Assoc Physicians India. 2013;61 (9):615-618.
65. Li CH, Chen WC, Liao WC, et al. The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study. QJM. 2015;108 (1):39-45.
66. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135(3):786-793.
67. Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;155(9):625-632.
68. Budweiser S, Harlacher M, Pfeifer M, et al. Co-morbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD. Copd. 2014;11(4):388-400.
69. Vitacca M, Paneroni M, Peroni R, et al. Effects of a multidisciplinary care program on disability, autonomy, and nursing needs in subjects recovering from acute respiratory failure in a chronic ventilator facility. Respir Care. 2014;59(12):1863-1871.
70. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34(4):812-818.
71. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761-767.
72. Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279-285.
73. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48(9):331-337.
74. Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis. PLoS One. 2015;10(9):e0136065.
75. Garcia-Aymerich J, Pitta F. Promoting regular physical activity in pulmonary rehabilitation. Clin Chest Med. 2014;35(2):363-368.
76. Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(6):622-629.
77. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006;119(10 Suppl 1):21-31.
78. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175(5):458-463.
79. Nguyen HQ, Chu L, Amy Liu IL, et al. Associations between physical activity and 30-day readmission risk in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(5):695-705.
80. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331-342.
81. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest. 2012;142(2):338-346.
82. Chawla H, Bulathsinghala C, Tejada JP, et al. Physical activity as a predictor of thirty-day hospital readmission after a discharge for a clinical exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(8):1203-1209.
83. Rehabilitation. AAoCP. Guidelines for Pulmonary Rehabilitation Programs Fourth Edition. Chicago (IL): American Association of Cardiovascular & Pulmonary Rehabilitation, Inc.; 2010. p. 45.
84. Casaburi R, Porszasz J, Burns MR, et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155(5):1541-1551.
85. Subin RV, Prem V, Sahoo. Effect of upper limb, lower limb and combined training on health-related quality of life in COPD. Lung India. 2010;27(1):4-7.
86. Wootton SL, Ng LW, McKeough ZJ, et al. Ground-based walking training improves quality of life and exercise capacity in COPD. Eur Respir J. 2014;44(4):885-894.
87. Rodriguez-Roisin R, Garcia-Aymerich J. Should we exercise caution with benzodiazepine use in patients with COPD? Eur Respir J. 2014;44(2):284-286.
88. De Sousa Pinto JM, Martin-Nogueras AM, Calvo-Arenillas JI, et al. Clinical benefits of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2014;34(5):355-359.
89. Lan CC, Huang HC, Yang MC, et al. Pulmonary rehabilitation improves subjective sleep quality in COPD. Respir Care. 2014;59 (10):1569-1576.
90. Cheng ST, Wu YK, Yang MC, et al. Pulmonary rehabilitation improves heart rate variability at peak exercise, exercise capacity and healthrelated quality of life in chronic obstructive pulmonary disease. Heart Lung. 2014;43(3):249-255.
91. Cameron-Tucker HL, Wood-Baker R, Owen C, et al. Chronic disease self-management and exercise in COPD as pulmonary rehabilitation: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2014;9:513-523.
92. Zwerink M, Van Der Palen J, Kerstjens HA, et al. A communitybased exercise programme in COPD self-management: two years follow-up of the COPE-II study. Respir Med. 2014;108(10):1481-1490.
93. Fletcher MJ, Dahl BH. Expanding nurse practice in COPD: is it key to providing high quality, effective and safe patient care? Prim Care Respir J. 2013;22(2):230-233.
94. Mannino DM. Biomarkers in COPD: the search continues! Eur Respir J. 2015;45(4):872-874.